CNCE - コンサ―ト・ファ―マシュ―ティカルズ (Concert Pharmaceuticals Inc.)

CNCEのニュース

   Enslaving stocks: Snap Inc. (NYSE:SNAP 9.48%), Concert Pharmaceuticals, Inc. (NASDAQ:CNCE 0.12%)  2023/03/07 12:32:50 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Enslaving stocks: Snap Inc. (NYSE:SNAP 9.48%), Concert Pharmaceuticals, Inc. (NASDAQ:CNCE 0.12%) appeared first on Stocks Equity .
   Sun Pharma completes acquisition of US-based Concert Pharmaceuticals  2023/03/06 17:09:00 Business Standard
Drug major Sun Pharma on Monday said it has completed the acquisition of US-based Concert Pharmaceuticals. In January, the Mumbai-based company inked a pact to acquire Concert in a USD 576 million deal. The drug major has successfully completed the acquisition of Concert Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company that is developing deuruxolitinib for the potential treatment of adult patients with moderate to severe alopecia areata, Sun Pharma said in a regulatory filing. "We are excited to add deuruxolitinib, a late-stage, potential best-in-class treatment for alopecia areata, to our growing global dermatology portfolio and expand our presence in the Boston biotech hub," Sun Pharma North America CEO Abhay Gandhi said. By bringing together Concert''s talented team with Sun Pharma''s global reach and commercial capabilities, this acquisition is an opportunity to bring deuruxolitinib to market globally and make a meaningful difference to alopecia areata patien
   Sun Pharmaceutical Completes Acquisition Of Concert Pharmaceuticals  2023/03/06 15:03:41 BQ Prime
Drug major Sun Pharma on Monday said it has completed the acquisition of U.S.-based Concert Pharmaceuticals.
   Sun Pharma Completes Acquisition of Concert Pharmaceuticals  2023/03/06 13:39:00 PR Newswire
Acquisition Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, to Sun Pharma''s Global Dermatology Portfolio MUMBAI, India and PRINCETON, N.J., March 6, 2023 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO,…
   Concert Pharmaceuticals Inc. (NASDAQ: CNCE): Aiming For A Higher Share Price  2023/03/04 13:30:00 Stocks Register
Concert Pharmaceuticals Inc. (NASDAQ:CNCE) shares, rose in value on Friday, 03/03/23, with the stock price up by 0.12% to the previous day’s close as strong demand from buyers drove the stock to $8.37. Actively observing the price movement in the last trading, the stock closed the session at $8.36, falling within a range of $8.35 … Concert Pharmaceuticals Inc. (NASDAQ: CNCE): Aiming For A Higher Share Price Read More »
   Concert Pharmaceuticals: Negative Spread But Interesting CVR  2023/02/16 18:54:09 Seeking Alpha
Concert Pharmaceuticals, Inc. is a biotech buyout trading at a negative spread but with an interesting CVR attached. Click here for my take on CNCE stock now.
   Concert retains breakthrough status for hair loss therapy despite rival entry  2023/02/15 18:54:20 Seeking Alpha
Concert Pharmaceuticals (CNCE) announced Wednesday that the FDA allowed it to keep the Breakthrough Therapy Designation for hair loss therapy deuruxolitinib. Read the full story here.
   Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata  2023/02/15 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert maintains deuruxolitinib breakthrough therapy designation from FDA for the treatment of alopecia areata.
   Watch this stock’s price performance: Concert Pharmaceuticals Inc. (NASDAQ:CNCE)  2023/02/09 20:00:00 US Post News
Currently, Concert Pharmaceuticals Inc.’s (CNCE) stock is trading at $8.34, marking a fall of -0.12% from last night’s close. At this price, the stock is -1.18% below its 52-week high of $8.44 and 224.51% above its 52-week low of $2.57. Based on the past 30-day period, the stock price is -1.18% below the high and […]
   SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations  2023/02/06 21:53:00 Kwhen Finance
   Concert Pharmaceuticals to Report Second Quarter 2021 Results on August 5, 2021  2021/07/29 11:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--The Company will host a conference call and webcast on August 5, 2021 to discuss its second quarter financial results and provide a business update.
   The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street  2021/07/20 12:19:55 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Aptose Biosciences Inc. (NASDAQ: APTO ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Ascendis Pharma A/S (NASDAQ: ASND ) Assembly Biosciences, Inc.
   The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs  2021/07/15 12:07:56 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) - U.K. antitrust regulators cleared its pending acquisition by AstraZeneca PLC (NASDAQ: AZN ) Bristol-Myers Squibb Company (NYSE: BMY ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Moderna, Inc. (NASDAQ: MRNA ) PLx Pharma Inc. (NASDAQ: PLXP ) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 14) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) ( announced a registered direct offering) Allogene Therapeutics, Inc. (NASDAQ: ALLO ) AlloVir, Inc. (NASDAQ: ALVR ) Aptose Biosciences Inc. (NASDAQ: APTO ) Avenue Therapeutics, Inc.
   The Daily Biotech Pulse: ScPharma''s Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues  2021/07/14 11:48:12 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) Biohaven Pharmaceutical Holding Company Ltd. . (NYSE: BHVN ) AngioDynamics, Inc. (NASDAQ: ANGO ) (reacted to its fiscal-year 2021 fourth-quarter results) Bicycle Therapeutics plc (NASDAQ: BCYC ) ( announced Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) exercised option to use its tissue-targeted delivery of oligonucleotide therapeutics tech) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Forward Pharma A/S (NASDAQ: FWP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) PLx Pharma Inc. (NASDAQ: PLXP ) (announced availability of FDA-approved liquid-filled aspirin capsules in Walmart Inc. (NYSE: WMT ) stores) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) Unicycive Therapeutics, Inc. (NASDAQ: UNCY ) (IPOed Tuesday) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 13) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc.
   The Daily Biotech Pulse: Lilly, Morphic''s Positive Data At ECCO, Humanigen''s COVID Treatment Gets Expedited Review In UK, TransCode IPO  2021/07/09 11:36:16 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO ) ( moved on positive analyst action) Ambrx Biopharma Inc. (NYSE: AMAM ) AtriCure, Inc. (NASDAQ: ATRC ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) BioLife Solutions, Inc. (NASDAQ: BLFS ) Edwards Lifesciences Corporation (NYSE: EW ) Novo Nordisk A/S (NYSE: NVO ) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 8) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) ADMA Biologics, Inc. (NASDAQ: ADMA ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) (announced positive Phase 2 data for non-alcoholic steatohepatitis drug) Allogene Therapeutics, Inc.

calendar